Application of ATP Infusions in Palliative Home Care

Application of Adenosine 5'-Triphosphate (ATP) Infusions in Palliative Home Care

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00565188

Enrollment

100

Registered

2007-11-29

Start date

2002-03-31

Completion date

2006-10-31

Last updated

2016-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Palliative Care, Quality of Life, Survival

Brief summary

Palliative care in cancer aims at alleviating the suffering of patients. A previous study in patients with advanced non-small-cell lung cancer showed that adenosine 5'-triphosphate (ATP) infusions had a favourable effect on fatigue, appetite, body weight, muscle strength, functional status, quality of life, and survival. Based on these promising results, the present study was designed 1. To evaluate whether the beneficial effects of ATP administration observed in patients with advanced lung cancer would also be present in pre-terminal cancer patients of different tumour types, and 2. To test the feasibility of application of ATP infusions in a home care setting.

Interventions

DRUGAdenosine 5'-triphosphate

Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* cytologically or histologically confirmed cancer * medical treatment options restricted to supportive care * a life expectancy \< 6 months * World Health Organization (WHO) performance status 1 or 2 * suffering from at least one of the following complaints: fatigue, weight loss \> 5% over the last 6 months, or anorexia

Exclusion criteria

* symptomatic angina pectoris * symptomatic heart failure * any form of atrioventricular (AV) block (assessed by electrocardiogram) * life expectancy \< 4 weeks * concurrent palliative chemotherapy * cognitive dysfunction, and other diseases hampering adequate follow up

Design outcomes

Primary

Measure	Time frame
Survival Physical restriction Fatigue Quality of life	0-8 weeks

Secondary

Measure	Time frame
Appetite Nutritional intake Body height Body weight Triceps skin fold thickness Mid-upper arm circumference Strength of elbow flexor and knee extensor muscles Handgrip strength Process evaluation	0-8 weeks

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026